ReviewExpert review of neurotherapeutics2018
Immune-based strategies for mood disorders: facts and challenges.
Review in Expert review of neurotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.Psychopharmacology · 2020Trial
- The Role of Mitochondrial Dysfunction-Mediated Changes in Immune Cytokine Expression in the Pathophysiology and Treatment of Major Depressive Disorder.Molecular neurobiology · 2025Review
- Immunopsychiatry of late life depression: role of ageing-related immune/inflammatory processes in the development and progression of depression.Acta neuropsychiatrica · 2025Review
- Psychoneuroimmunology of Mood Disorders.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Serum Levels of Zinc, Albumin, Interleukin-6 and CRP in Patients with Unipolar and Bipolar Depression: Cross Sectional Study.Current issues in molecular biology · 2024Article
- Blood epigenome-wide association studies of suicide attempt in adults with bipolar disorder.Translational psychiatry · 2024Article
- Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health.Neuroscience applied · 2024Review
- Targeting the Renin-Angiotensin System (RAS) for Neuropsychiatric Disorders.Current neuropharmacology · 2024Article
- Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review.Therapeutic advances in psychopharmacology · 2024Review
- Biomarkers of stress resilience: A review.Neuroscience applied · 2024Article
- Microbiota-gut-brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities.Molecular psychiatry · 2023Review
- Ovariectomy in mice primes hippocampal microglia to exacerbate behavioral sickness responses.Brain, behavior, & immunity - health · 2023Article
- Gut microbiota and its relation to inflammation in patients with bipolar depression: a cross-sectional study.Annals of general psychiatry · 2023Article
- T cells: an emerging cast of roles in bipolar disorder.Translational psychiatry · 2023Review
- Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders.Advances in experimental medicine and biology · 2023Review
- Regulatory role of cytokines on etiology of depression in animal models: their biological mechanisms and clinical implication with physical exercise.Journal of exercise rehabilitation · 2022Review
- The complex relationship between gut microbiota dysregulation and mood disorders: A narrative review.Current research in neurobiology · 2022Review
- Interleukin-8 and tumor necrosis factor-alpha in youth with mood disorders-A longitudinal study.Frontiers in psychiatry · 2022Article
- Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase.Metabolic brain disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionInflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.